Nan Fang

We’ve joined the second phase of #LiquidBX consortium. Funded by the Israel Innovation Authority רשות החדשנות, the consortium is aimed at uncovering key insights into the potential and possibilities of liquid biopsy testing for cancer care. In this phase, our focus will be on improving cancer detection and predicting treatment responses using advanced liquid biopsy technologies, alongside industry leaders Senseera, Identifai Genetics, Minovia Therapeutics , Salignostics, and MS Technologies Inc. Building upon our collaboration with the Hadassah Medical Center University Hospital Ein-Kerem, the consortium will generate a dataset featuring over 1,000 cases and more than seven omics readouts per sample, offering deeper understanding of cancer biology. We’re set to analyze and normalize mRNA expression data, contributing to the broader consortium efforts. With our ENLIGHT platform, we'll enhance our focus to include treatment response predictions, developing and validating innovative biomarkers once patient outcome data becomes available. Learn more via Webwire:  https://lnkd.in/gdXGVESt  #precisiononcology #personalizedmedicine #pangeabiomed #liquidbiopsies

10

Syncell is pleased to share that we will attend the GRC Single-Cell Cancer Biology conference. During the conference, Syncell will be showcasing our research poster titled "Identification of the novel immune synapse-localized proteome for immuno-oncology using Microscoop-induced targeted photo-biotinylation." This presentation highlights our innovative approach and the capabilities of Microscoop technology in identifying immune synapse-localized proteins, contributing to advancements in immuno-oncology research. This conference covers a wide range of important topics such as pre-malignancies and clonal evolution, intra-tumor heterogeneity, cell-cell interactions in the tumor microenvironment, technical advances in single-cell protocols and computational methods for data analysis and modeling, single-cell technologies in clinical practice, liquid biopsy, and single-cell multi-omics. We look forward to participating in insightful discussions and networking with fellow researchers at the GRC Single-Cell Cancer Biology conference. #Syncell #SingleCellCancer #ImmunoOncology #GRC2024

11

𝐅𝐥𝐨𝐰 𝐂𝐲𝐭𝐨𝐦𝐞𝐭𝐫𝐲 𝐌𝐚𝐫𝐤𝐞𝐭 𝐰𝐨𝐫𝐭𝐡 $10.3 𝐛𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 2032 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞: https://lnkd.in/dgt4XySv The size of global flow cytometry market in terms of revenue was estimated to be worth $5.1 billion in 2024 and is poised to reach $10.3 billion by 2032, growing at a CAGR of 9.2% from 2024 to 2032. 𝐂𝐨𝐦𝐚𝐩𝐧𝐢𝐞𝐬 𝐩𝐫𝐨𝐟𝐢𝐥𝐞 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭: Becton, Dickinson and Company Danaher Corporation Thermo Fisher Scientific Agilent Technologies Bio-Rad Laboratories Miltenyi Biotec Enzo Biochem Inc Sysmex Corporation bioMérieux CYTONOME ST. LLC Sartorius Cytek Biosciences Union Biometrica, Inc. Takara Bio Inc. Apogee Flow Systems Stratedigm, Inc. NanoCellect Biomedical, Inc. On-chip Biotechnologies Co., Ltd Nexcelom BennuBio, Inc. ORFLO Technologies Bay Biosciences LLC. BioLegend CytoBuoy

1

Final Presentation ! Dan Elbaum, Chief Scientific Officer at QurAlis, closed out the day with an incredible session on "Recent Advances in Splice-Switching Oligonucleotides for CNS Diseases." He covered: -PreRNA mis-splicing is a recurring theme in neurodegenerative diseases -Splice switching ASOs provide a powerful modality to correct these errors -QurAlis’ FlexASO™ platform enables the construction of splice switching ASOs with enhanced potency, safety, and biodistribution properties An incredible end to the conference, filled with cutting-edge insights! #OligoTherapeutics #OligoResearch #NucleicAcidTherapeutics #GeneTherapy #RNAi #ASOs #Biotechnology #PrecisionMedicine #PharmaInnovation #TherapeuticDevelopment #Biopharma #GeneticMedicine #MolecularBiology #OligoTx

5

1 Kommentar

In the latest edition of our "Medicinal Chemistry in Review" blog series, we describe the first fragment-based discovery of allosteric inhibitors of SHP2 by Astex. https://lnkd.in/eifniEns We hope you enjoy reading it. #Domainex #DrugDiscovery #MedChem

40